10.22.14
Biogen Idec
3Q Revenues: $2.5 billion (+37%)
3Q Earnings: $857 million (+76%)
YTD Revenues: $7.1 billion (+42%)
YTD Earnings: $2.1 million (+47%)
Comments: TECFIDERA revenues were $787 million in the quarter, up from $286.4 million in 3Q13, and consisting of $638 million in U.S. sales and $149 million outside the U.S. TYSABRI revenues were $501 million, up 25%. U.S. sales were $275 million and $226 million outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $745 million, consisting of $482 million in U.S. sales and $263 million in sales outside the U.S. Net revenues for the unconsolidated joint business arrangement for RITUXAN and GAZYVA were $291 million in the quarter.
3Q Revenues: $2.5 billion (+37%)
3Q Earnings: $857 million (+76%)
YTD Revenues: $7.1 billion (+42%)
YTD Earnings: $2.1 million (+47%)
Comments: TECFIDERA revenues were $787 million in the quarter, up from $286.4 million in 3Q13, and consisting of $638 million in U.S. sales and $149 million outside the U.S. TYSABRI revenues were $501 million, up 25%. U.S. sales were $275 million and $226 million outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $745 million, consisting of $482 million in U.S. sales and $263 million in sales outside the U.S. Net revenues for the unconsolidated joint business arrangement for RITUXAN and GAZYVA were $291 million in the quarter.
